Table 3.
Immunogenicity of the QazCovid-in® vaccine in phase 3 study measured by MNA and ELISA, PP population.
| Days after the first immunisation | Vaccine GMT % seroconversion |
Placebo GMT % seroconversion |
Vaccine/Placebo GMT ratio (95% CI) % seroconversion ratio (95% CI) |
|||
|---|---|---|---|---|---|---|
| MNA | ELISA | MNA | ELISA | MNA | ELISA | |
| Day 1 | 1·0 n/a * |
1·0 n/a |
1·0 n/a |
1·0 n/a |
1·0 (1·0, 1·0) n/a |
1·0 (1·0, 1·0) n/a |
| Day 21 | 17·1 99 |
169·7 99 |
1·4 11 |
1·8 16 |
12·6 (11·6, 13·8) 9·0 (7·2, 11·4) |
97·0 (83·0, 113·3) 6·1 (5·1, 7·4) |
| Day 42 | 109 99 |
711·3 100 |
2·3 24 |
3·1 26 |
47·6 (43·3, 52·3) 4·1 (3·5, 4·7) |
228·9 (200·7, 261·0) 3·8 (3·3, 4·3) |
| Day 90 | 47·3 99 |
48·3 99 |
2·8 29 |
3·8 30 |
16·7 (15·1, 18·3) 3·4 (3·0, 3·9) |
91·4 (79·6, 105·0) 3·3 (2·9, 3·7) |
| Day 180 | 9·1 64 |
32.8 76 |
4·3 37 |
8·6 40 |
2·1 (1·8, 2·5) 1·7 (1·5, 1·9) |
3·8 (3·0, 4·9) 1·9 (1·7, 2·1) |
⁎
n/a – not applicable.
95% CI for GMT ratio was calculated based on the 95% CI for difference between means of logarithmic values with assumption that the variances in the populations are similar.
95% CI for %seroconversion ratios was calculated using the Koopman asymptotic score confidence interval for the ratio of proportions as implemented in the GraphPad Prizm v8.4.8.